In a sense, Johnson & Johnson 's acquisition of DePuy Inc. is the deal everyone in orthopedics was waiting for: a bold acquisition by one of the middle-tier players that could begin to consolidate an industry that is arguably too fragmented to continue profitably [See Deal].)
Still, just six months ago, there were rumors that Johnson & Johnson itself was uncertain what kind of future, if any, it wanted in orthopedics. (See "What's Next for J&J's...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?